<DOC>
	<DOCNO>NCT02690155</DOCNO>
	<brief_summary>To obtain good understand comparative effectiveness rivaroxaban versus VKA ( Vitamin K antagonist ) stroke prevention patient NVAF ( non-valvular atrial fibrillation ) real-life set</brief_summary>
	<brief_title>Real-world Comparative Effectiveness Rivaroxaban Versus VKA</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>NVAF ( nonvalvular atrial fibrillation ) define occurrence 2 inpatient outpatient claim ICD ( International Classification Disease ) 9 427.31 diagnosis code time patient 's data history prior inclusion Patients require 180 day enrollment assessment baseline characteristic CHA2DS2Vasc score â‰¥2 180 day prior index rivaroxaban use baseline period ( CHA2DS2Vasc : Diabetes mellitus ; S2 : prior Stroke TIA Thromboembolism ; V : Vascular disease ; A : Age 6574 year ; Sc : Sex category ) Patients &lt; 18 year age Patients valvular AF ( Atrial fibrillation ) Pregnancy Malignant cancer Transient cause AF Patients venous thromboembolism ( pulmonary embolism deep vein thrombosis ) Patients major surgery define hip knee replacement Prescriptions oral anticoagulant ( OACs ) ( apixaban , warfarin , dabigatran , rivaroxaban ) index date Prescription one OAC index date Patient event define composite endpoint Fatal bleeding Fatal Stroke/Myocardial infarction Intracranial hemorrhage Ischemic stroke Myocardial infarction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-valvular atrial fibrillation ( NVAF )</keyword>
	<keyword>Prevention</keyword>
	<keyword>Stroke</keyword>
</DOC>